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Aluminum and Manganese 
As Neurotoxicants
Aluminum (Al) and manganese (Mn) are
neurotoxicants that have the potential to
contribute to neurodegenerative disorders
(1–5). The contributory role of Al in the
dialysis encephalopathy syndrome has been
shown. Avoidance of the major Al sources
contributing to the syndrome has greatly
reduced this problem, although occasional
outbreaks still occur (6). There has been
concern about the suggested role of Al in
Alzheimer disease (AD) since the initial
report of elevated brain Al in victims of this
condition (7). Some studies have shown a
small positive correlation between drinking-
water Al concentration and dementias,
including AD [reviewed by Yokel (2)].
However, the role of Al in AD etiology is
highly controversial because of the conflict-
ing results of studies of brain Al of AD vic-
tims, the association of drinking-water Al
and the risk for AD, and other reported end
points of Al toxicity. As a result of contin-
ued concern about the neurotoxicity of Al,
the U.S. Environmental Protection Agency
has put Al on its contaminant candidate list,
the U.S. Food and Drug Administration
recently implemented labeling requirements
for Al in large- and small-volume parenter-
als, and Canada established operational
guidance limits for drinking-water Al on the
basis of the precautionary principle (8–10).
Manganese can produce a parkinsonism-
like syndrome (11,12). This has occurred in
miners after prolonged exposed to manganese
dioxide by inhalation (13), families drinking
well water contaminated by buried dry-cell
batteries [cited by Hudnell (11)], workers in
dry-cell battery factories, and perhaps from
environmental exposure (14). There is cur-
rently concern about airborne exposure from
the use of Mn in fungicides such as ethylene-
bis(dithiocarbamato)manganese (Maneb;
Cerexagri, Inc., King of Prussia, PA, USA)
and in the fuel-additive octane-enhancer
methylcyclopentadienyl manganese tricar-
bonyl (MMT) (11). The use of MMT in the
United States has been permitted by a court
decision (Ethyl Corporation v. Carol M.
Browner, Administrator of the United States
Environmental Protection Agency, and the
United States Environmental Protection
Agency. 1995. Case No. 94-1516, U.S.
Court of Appeals for District of Columbia
Circuit, Washington, DC), although MMT
has apparently not been extensively used as a
fuel additive in the United States since the
decision. In contrast to Al, for which no
mammalian essentiality has been shown, Mn
is essential, required for brain development
and function (15).
There was very little published information
on the sites and mechanisms of brain Al entry
prior to our initiation of such studies, and
nothing on efflux from the brain. My col-
leagues and I have elucidated the predominant
site and have investigated the rates and mecha-
nisms of blood–brain barrier (BBB) perme-
ation of Al, as well as the duration of Al
retention in the brain. Brain Mn uptake has
been attributed to a carrier-mediated process
[reviewed by Aschner and colleagues (16,17)].
However, the studies were not conducted
under conditions that controlled the Mn
species, leaving uncertainty about the Mn
species that enter the brain. There have been
no reports of studies of Mn efflux from
the brain.
The Sites and Mechanisms 
of Metal Distribution into 
the Brain
The potential routes that substances may
distribute from the nasal cavity into the
brain include absorption into systemic circu-
lation followed by permeation through the
BBB or choroid plexuses, and absorption
from the nasal cavity into olfactory nerves
followed by neuronal distribution directly
into the brain. The ability of Al to enter the
brain via this latter route has been addressed
in two preliminary studies (18,19). In con-
trast, Mn has been shown to slowly enter the
brain via this route, although quantitation
(bioavailability) has not been reported (20,21).
Al and Mn may enter the brain from
blood, either through the choroid plexuses or
the BBB. These routes of distribution
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My colleagues and I investigated the sites and mechanisms of aluminum (Al) and manganese
(Mn) distribution through the blood–brain barrier (BBB). Microdialysis was used to sample
non–protein-bound Al in the extracellular ﬂuid (ECF) of blood (plasma) and brain. Brain ECF Al
appearance after intravenous Al citrate injection was too rapid to attribute to diffusion or to
transferrin-receptor–mediated endocytosis, suggesting another carrier-mediated process. The
brain:blood ECF Al concentration ratio was 0.15 at constant blood and brain ECF Al concentra-
tions, suggesting carrier-mediated brain Al efflux. Pharmacological manipulations suggested the
efflux carrier might be a monocarboxylate transporter (MCT). However, the lack of Al 14C-cit-
rate uptake into rat erythrocytes suggested it is not a good substrate for isoform MCT1 or for the
band 3 anion exchanger. Al 14C-citrate uptake into murine-derived brain endothelial cells
appeared to be carrier mediated, Na independent, pH independent, and energy dependent.
Uptake was inhibited by substrate/inhibitors of the MCT and organic anion transporter families.
Determination of 26Al in rat brain at various times after intravenous 26Al suggested a prolonged
brain 26Al half-life. It appears that Al transferrin and Al citrate cross the BBB by different mecha-
nisms, that much of the Al entering brain ECF is rapidly efﬂuxed, probably as Al citrate, but that
some Al is retained for quite some time. Brain inﬂux of the Mn2+ ion and Mn citrate, determined
with the in situ brain perfusion technique, was greater than that attributable to diffusion, sug-
gesting carrier-mediated uptake. Mn citrate uptake was approximately 3-fold greater than the
Mn2+ ion, suggesting it is a primary Mn species entering the brain. After Mn2+ ion, Mn citrate,
or Mn transferrin injection into the brain, brain Mn efflux was not more rapid than that pre-
dicted from diffusion. The BBB permeation of Al and Mn is mediated by carriers that may help
regulate their brain concentrations. Key words: aluminum, b.End5 cells, blood–brain barrier,
brain efﬂux, brain endothelial cells, brain inﬂux, in situ brain perfusion, manganese, microdialy-
sis, rat. Environ Health Perspect 110(suppl 5):699–704 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-5/699-704yokel/abstract.html
Brain Uptake, Retention, and Efﬂux of Aluminum and Manganese
Robert A. Yokel
College of Pharmacy and Graduate Center for Toxicology, University of Kentucky Medical Center, Lexington, Kentucky, USA700 VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 • Environmental Health Perspectives
between blood and brain are shown diagram-
matically in Figure 1. There is a choroid
plexus in each of the four cerebral ventricles
of the brain. They synthesize most of the
cerebrospinal fluid (CSF) that fills the brain
ventricles and the subarachnoid space that
surrounds the brain and spinal cord. The
total surface area of the choroid plexuses is
approximately 10 cm2. Brain atlases of the rat
and human show brain regions as far as 1 mm
away from the nearest component of the CSF
compartment.
The BBB provides the other route of
distribution from blood to brain. The
anatomical basis of the BBB is primarily
attributed to the tight junctions between the
cerebral microvascular endothelial cells that
line the microvessels that perfuse the brain.
Additional impediments to permeation
through the BBB come from the absence of
fenestrations and the low transcytotic activity
of the endothelial cells, the pericytes that sur-
round 30% of their surface, and the astrocyte
foot processes that cover 99% of the surface
of the endothelial and pericyte cells.
Substances must either diffuse through the
membranes of these cells or be transported by
cell membrane carriers to penetrate the BBB.
The surface area of the 400 miles of brain
capillaries that are the site of the BBB is
roughly 12 m2, about 1,000-fold that of the
choroid plexuses. Visual examination of elec-
tron micrographs suggests that no cell in the
brain is >30–40 µm from the nearest
microvessel (BBB site) (22). There is much
greater opportunity for rapid exchange
between blood and brain through the BBB
than through the choroid plexuses and
CSF compartment.
The potential mechanisms of distribution
of substances across the BBB are the same as
those across any cell membrane: diffusion,
carrier- and receptor-mediated transport by
facilitated diffusion, and active transport.
The roles of lipophilicity (hydrogen bonding
potential, polar surface area) and molecular
weight (size) as predictors for diffusion
of small molecules across the BBB have been
well described (23,24), providing the
opportunity to estimate the permeability
rates of Al, Mn, and their complexes across
the rat BBB from their octanol/buffer parti-
tioning coefficient and molecular weight
(23). Studies have identiﬁed carrier-mediated
transport of some metals through the BBB,
including copper as an L-histidine complex,
iron by transferrin-receptor–mediated endo-
cytosis (TfR-ME), mercury as a cysteine
complex, and zinc as an amino acid complex
(25). These suggest the possibility that Al,
Mn, and/or their complexes may cross the
BBB by carrier-mediated transport. We con-
ducted studies in rats and in cells derived
from the BBB to elucidate the distribution of
Al and Mn into and out of the brain and the
mechanisms mediating these processes.
Animal work was approved by the University
of Kentucky Institutional Animal Care and
Use Committee and was conducted follow-
ing the Guiding Principles in the Use of
Animals in Toxicology of the Society of
Toxicology (26).
The Predominant Site of
Aluminum Distribution into
and out of the Brain
We initially studied Al distribution across the
rat BBB using microdialysis probes implanted
in the frontal cortex, lateral ventricle, and
blood (jugular vein). This provided the ability
to sample the extracellular fluid (ECF) in
those compartments and therefore in the ﬂu-
ids on both sides of the BBB and a choroid
plexus. Microdialysis provides a reﬂection of
unbound substances in the ECF. It was used
because it enables repeated sampling and
therefore determination of distribution across
the BBB and choroid plexus at multiple time
points within the same subject. The substance
concentrations in dialysates exiting the brain
or CSF compared with blood were used to
generate a brain:blood ratio (BBr).
It has been pointed out that consideration
of the chemical species of a metal in a
bioﬂuid indicates the species available to dis-
tribute across membranes, such as the BBB,
and that might serve as substrates for carriers
(25). Speciation calculations conducted
by Wesley Harris [cited by Yokel and
McNamara (27)] indicated that 91% of
plasma Al is Al transferrin and 7–8% is Al
citrate, whereas 90% of Al in brain ECF was
predicted to be Al citrate and only 4% Al
transferrin. Al citrate was administered in the
microdialysis studies. The Al concentration in
the dialysate exiting the frontal cortex micro-
dialysis probe reached a maximal steady value
in the ﬁrst 5-min sample after Al citrate was
given as an intravenous bolus, indicating
quite rapid distribution of Al from blood to
brain ECF (Figure 2A). The microdialysis
probe in the frontal cortex was some distance
from the cerebral ventricles where Al might
enter the CSF from a choroid plexus.
Maximal penetration of substances through
brain parenchyma is thought to be <1 mm
(28), perhaps in part due to a bulk flow of
ECF from brain parenchyma toward the cere-
bral ventricles (29). The appearance of the
maximal value within 5 min in the frontal
cortex suggests entry through the BBB.
However, there is evidence of rapid distribu-
tion of solutes from CSF to the brain ECF
surrounding the microvasculature. This dis-
tribution is believed to occur through the par-
avascular space (30). Comparison of the Al
concentration in the dialysates obtained from
the frontal cortex versus the CSF and com-
parison of the Al BBr calculated from
brain/blood and CSF:blood ratio for each
sample interval (Figure 2B) revealed a higher
Al concentration, and higher BBr, in the
frontal cortex than in CSF. This supports the
suggestion that Al enters the brain from
blood through the BBB rather than through
the choroid plexuses because entry through
the choroid plexus and diffusion through the
brain would not be expected to produce a
higher Al concentration in the frontal cortex
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Figure 1. The routes of distribution between plasma
and brain: through the BBB and the choroid plexus
(CP). Arrows show membranes through which dis-
tribution might occur by carrier-mediated transport
in addition to diffusion. The dashed line depicts the
absence of a membrane barrier to distribution
between the CSF and brain ECF.
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Figure 2. Aluminum concentration determined by atomic absorption spectrometry in three compartments
of rats simultaneously and repeatedly using microdialysis after a bolus intravenous Al injection. (A) Al con-
centration in dialysates exiting from microdialysis probes implanted in blood ECF (plasma; circles), brain
ECF (squares), and the lateral ventricle CSF (triangles), after an intravenous bolus injection of 0.5 mmol Al
citrate/kg. (B) BBr of Al for the results shown in A: brain ECF:blood (diamonds) and CSF:blood (inverted tri-
angles). Values shown are mean ± SEM of at least three animals at each time. Lines show two-term non-
linear regressions in A and one-term nonlinear regressions in B. From Allen and Yokel (53). Published with
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than in the CSF. The frontal cortex BBr was
consistently <1, suggesting a process other
than diffusion was mediating Al transfer
across the BBB.
Further evidence of carrier-mediated
distribution of Al across the BBB was
obtained based on the calculated plasma Al
concentration in the microdialysis studies
(1 mM), the rate of Al citrate flux through
membranes (4 × 10–16 mol/cm2/sec) (31), the
brain capillary surface area (240 cm2/g brain)
(32), and brain ECF volume (0.15 mL/g
brain). Calculating the amount of Al that
would diffuse across the BBB in 5 min from
1 mL of blood into 0.15 mL of ECF pro-
vided an estimate of the resultant Al concen-
tration in the brain ECF. When compared
with the blood Al concentration, this pro-
duced a BBr of 0.00003. This is much less
than the observed BBr of approximately 0.15.
To further assess Al distribution across
the BBB from the relationship between brain
and blood ECF Al concentrations, Al citrate
was bolus dosed and infused at various rates.
This achieved quite constant Al concentra-
tions in the sampled compartments, shown
by the consistent Al concentration over time
in the dialysates exiting microdialysis probes
in the brain and blood. Plasma and brain
ECF Al concentration increased proportion-
ally to the increase in the Al infusion rate
(Figure 3A), suggesting linear (concentration
independent) Al distribution and elimination.
However, the BBr was consistently approxi-
mately 0.15, signiﬁcantly less than 1 (Figure
3B). These results support the hypothesis that
Al BBB permeation is carrier mediated
because at steady state the concentration of Al
in blood ECF (plasma) × the brain inﬂux rate
must equal the concentration of Al in brain
ECF × the brain efﬂux rate. Because the con-
centration of Al in blood ECF was greater
than the concentration of Al in brain ECF,
the brain influx rate must be less than the
efﬂux rate. Therefore, BBB permeation of Al
cannot be attributed solely to diffusion.
Efflux of Al from the brain also likely
occurs across the BBB rather than through
CSF. In these studies it was necessary to
administer doses of Al citrate that exceeded
physiological Al and citrate concentrations
and exceeded the metal-binding capacity of
transferrin. These high concentrations were
necessary to reliably quantitate increases in
Al above its background concentration, con-
sidering the low relative recovery of Al citrate
(~3.25%) by microdialysis (33). The calcu-
lated plasma Al concentration at the highest
Al citrate infusion rate was approximately 1
mM. Because the Al was introduced as Al
citrate, and it is estimated transferrin could
not have complexed more than 15% of the
Al in plasma at the lowest Al blood level and
only 2% at the highest, it is likely that most
Al in plasma and essentially all in brain ECF,
where the transferrin concentration is <1%
of that in plasma, was associated with citrate.
The Al recovered by microdialysis could not
have been Al transferrin because transferrin is
too large to penetrate the membrane of the
microdialysis probes we used. The marker of
BBB permeability included in most of these
studies, 4-trimethylammonium antipyrine
(34), did not indicate that BBB integrity was
significantly compromised. These results
suggest Al citrate can enter the brain from
blood through the BBB by a mechanism
other than diffusion.
Mechanism(s) of Aluminum
Distribution across the BBB
Many carriers have been reported at the BBB
(35). A review of these carriers suggests some
candidates that might mediate Al citrate
transport across the BBB, including TfR-ME.
However, Al citrate can also enter the brain
by one or more other mechanisms. Assuming
that TfR-ME clears Al from blood into brain
ECF across the BBB at the same rate as it
clears iron [3 × 10–3 mL blood/gm brain/hr
(36)], the Al that could enter brain ECF from
blood in 5 min would result in a BBr of
0.0004 based on estimated plasma ECF Al
concentrations up to 1 mM from our micro-
dialysis results. The observed BBr was much
greater than this value. Calculation of Al spe-
ciation at pH 7.4 showed approximately 1.25
and 29% of the Al would be present as
Al(H–1citrate)– and Al(H–1citrate)(OH)2–,
respectively, in the presence of 1 mM citrate.
The percentage of these species would
increase at lower Al citrate concentrations
(37). In these complexes there is a single,
noncomplexed, ionized carboxylate group.
The presence of this monocarboxylate sug-
gested that Al citrate may be a substrate for
the monocarboxylate transporter (MCT) at
the BBB. At least one MCT isoform, MCT1,
has been shown to be expressed at the BBB.
The reported rate of substrate transfer by the
MCT across the BBB, 60 nmol/g brain/min,
could transport 40,000 ng Al, as the citrate,
into 1 mL brain ECF in 5 min after the intra-
venous bolus Al injection described above if
Al citrate serves as a comparably transported
substrate. This is about 15 times the esti-
mated rate of appearance of Al in brain ECF
that we observed. This calculation is based on
the observed 2.8 mM Al in frontal cortex
dialysate within 5 min of intravenous Al cit-
rate injection and an estimated 3.25% relative
recovery, yielding an estimated 2,520 ng
Al/mL ECF.
To test the hypothesis that MCT1
mediates Al citrate transport across the BBB,
substances were included in the dialysate of
the microdialysis probe implanted in the
frontal cortex of rats that were receiving an
intravenous infusion of Al citrate. These sub-
stances were expected to diffuse from the
dialysate into the brain to achieve sufficient
concentrations to produce local effects in the
same brain region where BBB function was
being studied. Addition of 15 µM CN– or
10 µM 2,4-dinitrophenol, as metabolic
inhibitors, 1 M pyruvate as a substrate for the
MCT, and a pH 10.2 dialysate or 1 mM car-
bonylcyanide-p-(trifluoromethoxy)phenyl-
hydrazone to reduce proton availability and
proton gradients significantly increased the
BBr to approximately 1 (38,39). Similar
increases in the BBr were not observed in the
contralateral frontal cortex nor was the
integrity of the BBB significantly compro-
mised. These results suggest inhibition of an
energy-dependent process, competition for
MCT transport, and reduction of protons
inhibited carrier-mediated Al citrate transport
across the BBB, leaving only diffusion medi-
ating its BBB permeation. The results were
consistent with the hypothesis that Al citrate
is a substrate for MCT-mediated transport
across the BBB. To further test this hypothe-
sis, studies were conducted with the rat ery-
throcyte because it expresses MCT1 and the
band 3 anion exchange transporter. However,
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Figure 3. Steady-state Al concentrations determined by atomic absorption spectrometric analysis of
microdialysis samples from the brain and blood of rats during intravenous infusion of four Al citrate con-
centrations. (A) Steady-state Al concentration in dialysate exiting microdialysis probes implanted in blood
ECF (plasma; circles) and brain ECF (squares) at various infusion rates of Al citrate. (B) Steady-state BBr of
Al for the results shown in A. Values shown are means ± SEM of ﬁve animals at each infusion rate. Lines
show linear regressions. From Allen et al. (54).the uptake of a known substrate, 14C-lactate,
was not inhibited by Al citrate, nor was there
significant uptake of Al 14C-citrate. These
results suggest Al citrate is not an effective
substrate for either MCT1 or the band 3
anion exchange transporter.
To characterize, and perhaps identify, the
carrier(s) mediating Al citrate transport across
the BBB, Al citrate uptake studies were con-
ducted using b.End5 cells, an immortalized
cell line derived from murine brain endothe-
lial cells. Al 14C-citrate uptake was slow and
reasonably linear for 4 hr. Uptake of Al 14C-
citrate was approximately 70% greater than
14C-citrate uptake. Uptake after 1 hr achieved
an intracellular Al citrate concentration of
approximately 25% of the medium concen-
tration. In comparison, diffusion was calcu-
lated to produce an intracellular Al citrate
concentration of approximately 1% of the
medium concentration. These results
suggested carrier-mediated uptake.
Al 14C-citrate uptake into b.End5 cells
was pH independent, sodium independent,
and energy dependent and was inhibited by
numerous nonspecific substrates and
inhibitors of MCT and organic anion trans-
porters. Uptake was concentration depen-
dently inhibited by two relatively specific
organic anion transporter substrates (37).
Comparison of the characteristics of the car-
rier(s) mediating Al citrate uptake to those of
carriers described at the BBB suggests Al cit-
rate transport may be mediated by an organic
anion transporter such as an MCT isoform
and/or an organic anion–transporting
polypeptide (oatp). Further work elucidating
which of the MCT and oatp isoforms are
expressed at the BBB and the identification
of isoform-selective inhibitors that could be
used in future studies of Al citrate uptake
into brain endothelial cells or the brain
would advance the ability to identify the
BBB Al citrate transporter(s).
Some Aluminum Persists in
the Brain for a Long Time
We conducted a study to ascertain the
residence time of Al in the brain.
Administration of the stable, ubiquitous iso-
tope of Al, 27Al, is not well suited to deter-
mine the brain half-life of Al because brain
Al concentrations are relatively small and do
not greatly increase in response to Al expo-
sure. Therefore, an elevation above, and sub-
sequent decrease toward, the endogenous Al
concentration is difficult to reliably deter-
mine. The natural abundance of 26Al is
extremely small. 26Al can be quantiﬁed with
exquisite sensitivity (~1 × 106 atoms) as the
26Al:27Al isotopic ratio by accelerator mass
spectrometry (AMS), enabling the study of
Al toxicokinetics at physiologically relevant
Al exposures (40). A disadvantage is the cost
of AMS analysis of 26Al (~$200/sample). We
gave rats intravenous 26Al transferrin or 26Al
citrate and terminated them from 4 hr to
256 days later to determine the percentage of
Al in blood that enters the brain, the time
course of Al efflux from the brain and
whether brain Al clearance is enhanced by
repeated chelation therapy with desferriox-
amine, a clinically-useful Al chelator. The
peak brain 26Al concentration, approximately
0.005% of the 26Al dose per gram of brain,
was similar after 26Al transferrin and 26Al cit-
rate dosing and was similar to some previous,
smaller, short-term studies (41). The compa-
rable results from Al citrate and Al transfer-
rin are probably due to the change in the Al
ligand from citrate to transferrrin, the pre-
ferred ligand, within minutes because the
administered Al citrate dose was only about
1% of the plasma transferrin metal-binding
capacity. The half-life of brain 26Al could not
be accurately calculated but was estimated to
be about 150 days. The brain half-life was
roughly 55 days in rats that received desfer-
rioxamine injections three-times weekly,
demonstrating brain Al retention in com-
partments from which it can be mobilized
(Figure 4). It is difﬁcult to extrapolate these
results to the human because of the lack of
comparable metal half-life determinations in
rat versus human brain or sufficient insight
into allometric scaling from rat to human
brain for metals. The residence of Al in the
brain and other soft tissue organs may reﬂect
the residence of Al in bone, which contains
approximately 50–70% of the Al body bur-
den. The bone 26Al half-life is prolonged in
the rat (42).
Manganese Citrate Enters
the Brain by a Carrier-
Mediated Process
We recently began studies of Mn distribution
across the BBB. Brain uptake of small-
molecular-weight Mn species was previously
attributed to a carrier-mediated process, but
the work was not conducted under condi-
tions that controlled the Mn species (43,44).
The experimental approach we employed was
to compare brain inﬂux and efﬂux rates deter-
mined in the rat to BBB permeation rates
predicted for capillary diffusion to ascertain if
there was evidence for carrier-mediated inﬂux
or efflux of Mn. To study brain Mn uptake
under conditions where better control of the
Mn species could be maintained, we used
54Mn species and the in situ brain perfusion
technique (45), as modified by Allen and
Smith (46). Brain inﬂux of the Mn2+ ion and
Mn citrate, which were calculated to repre-
sent 40 and 12%, respectively, of non–pro-
tein-bound Mn in plasma (47), were studied,
as well as Mn transferrin. The brain uptake
rates determined in the intact rat were com-
pared with the estimated brain capillary diffu-
sion rates of these Mn species, which were
calculated from the their molecular weight
and lipophilicity (Figure 5). Lipophilicity was
determined as the partitioning coefficient
between octanol and an aqueous phase. The
estimated brain capillary diffusion rates were
then calculated from the relationship between
molecular weight and lipophilicity for sub-
stances that diffuse through the BBB (23)
times the brain capillary surface area (240
cm2/g brain). The estimated brain capillary
diffusion rates of the Mn ion, Mn citrate, and
Mn transferrin ranged from 1.5 to 2.8 × 10–5
mL/sec/g (48).
The average observed brain uptake rates
of the Mn citrate, Mn ion, and Mn trans-
ferrin into the nine brain regions sampled
were 25, 8.6, and 5.7 × 10–5 mL/sec/g,
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Figure 4. Brain 26Al determined by AMS in rats
terminated at various times after intravenous
administration of 26Al transferrin. The rats received
an injection of saline 3 times weekly (squares) or
0.15 mmol/kg desferrioxamine (circles). Values are
the means ± SEM of results from four to six rats
and are shown as the percentage of the injected
26Al per gram of brain. From Yokel et al. (41) with
permission of Oxford Press.
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Figure 5. The brain (parietal cortex) uptake rates
for three Mn species determined after their intra-
venous infusion as 54Mn in the rat, using the in situ
brain perfusion method. The rat received an intra-
arterial perfusion for a variable duration (shown) of
one of the three Mn species: Mn citrate (dia-
monds), Mn transferrin (triangles), or Mn2+ ion (cir-
cles). Values are mean from 7–11 rats per data
point except for Mn citrate (diamonds), n = 4 for 90
sec. The symbols for Mn transferrin and Mn citrate
at 30 and 60 min are shown slightly to the left and
right, respectively, of their true values to enable
their visualization. Squares show upper and lower
range of brain uptake predicted for these three Mn
species for capillary diffusion. Lines are best-ﬁtted
linear regressions of the means.respectively, suggesting carrier-mediated
uptake of each Mn species. To verify that Mn
was entering the brain, compared to being
adsorbed onto or taken into but not through
brain endothelial cells, the capillary depletion
method was used to separate brain capillary
cells from the rest of the brain (49). Only
8–25% of the Mn was associated with capil-
lary cells, suggesting the in situ brain perfu-
sion studies were showing Mn distribution
across the BBB (47).
Brain Manganese Efﬂux 
Does Not Appear to Be 
Carrier Mediated
The efﬂux of Mn out of the brain across the
BBB was determined using an established
method (50). Efﬂux through brain capillaries
(the BBB) was calculated from the product of
the volume of distribution of the Mn within
the brain, from which it can efﬂux to blood,
times the brain elimination rate constant. The
volume of Mn distribution in the brain was
determined from uptake of 54Mn as the ion,
citrate, and transferrin into rat parietal brain
slices versus time. In contrast to brain slice
uptake of para-aminohippurate, which reached
a plateau at approximately 60 min (51), uptake
of these Mn species continued to increase for
up to 180 min, suggesting continued brain cell
uptake. The brain elimination rate constant of
these three Mn species was determined from
the percentage of 54Mn remaining in the brain
at various times after injection as 54Mn ion,
citrate, or transferrin into the parietal cortex,
compared with the percentage of 14C-sucrose
or 14C-dextran, which are expected to very
slowly efﬂux from the brain by diffusion across
the BBB. The Mn species did not efﬂux from
the brain more rapidly than sucrose or dextran.
Taken with the parietal slice uptake results, the
lack of brain efﬂux suggests Mn continues to
be taken up into brain cells over time and is
not transported out of the brain by carrier-
mediated processes (52).
Carriers Mediate the
Permeation of Aluminum
and Manganese across the
BBB
The results of the studies reviewed herein
suggest that there are carriers at the BBB that
mediate the uptake of Al and Mn into the
brain. This may be a beneficial process for
Mn, an essential element for brain metabo-
lism. However, Al is not essential and, like
Mn, is neurotoxic when sufﬁcient brain con-
centrations are achieved. The results suggest
that there is a carrier-mediated mechanism to
protect the brain from Al, by effluxing it
across the BBB into blood. It does not
appear that a similar protective mechanism is
present for Mn. Further work is necessary to
identify the carriers mediating transport of
these metals across the BBB.
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